Close Menu
    What's Hot

    Longevity & Mortality Investor Conference 2026

    May 19, 2026

    Leeds Building Society Staff Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

    May 18, 2026

    International Life Settlement Forum 2026

    May 18, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Will the US Asset Intensive Life Reinsurance Market Continue Recent Growth Spurt?

      April 22, 2026

      Daiichi Life to Reinsure Whole Life Block with Prismic Life

      April 13, 2026

      Reporting Change to Provide Regulators With More Transparency into US/Offshore Asset-Intensive Life Reinsurance Treaties

      January 28, 2026

      Capital Markets Investors Could Be About to Get a Slice of UK Life Insurance Risk

      November 26, 2025

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      Life Settlement Secondary Market Returns to Growth but Plenty of Untapped Potential Still Remains

      April 22, 2026

      EIOPA Sets Out Views on Private Equity Ownership of Life Insurers in New Consultation Paper

      March 25, 2026

      Leeds Building Society Staff Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

      May 18, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026
      Just Group

      Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

      May 11, 2026

      Bakkavor Pension Scheme Completes Bulk Purchase Annuity Buy-In With Rothesay

      May 5, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

      March 25, 2026

      Business as Usual in UK Pension Risk Transfer Market Amid Record Low Mortality in England and Wales

      March 25, 2026

      Latest CMI Model Shows Further Rise in Cohort Life Expectancy

      March 11, 2026

      LISA Files Amicus Brief Highlighting Consumer Impact of Adverse Ruling Regarding Term Life Insurance Policies

      May 18, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026

      UK Equity Release Market Origination Slows To Begin 2026

      May 6, 2026

      Longevity & Mortality Investor Conference 2026

      May 19, 2026

      Leeds Building Society Staff Pension Scheme Completes Bulk Purchase Annuity Buy-In With Royal London

      May 18, 2026

      International Life Settlement Forum 2026

      May 18, 2026

      LISA Files Amicus Brief Highlighting Consumer Impact of Adverse Ruling Regarding Term Life Insurance Policies

      May 18, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026

      Editor’s Letter – Volume 2, Issue 2, February 2026

      February 11, 2026

      Editor’s Letter – Volume 2, Issue 1, January 2026

      January 14, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    US Life Insurance Industry Retreats Slightly in 2024 but Remains Healthy Fundamentally

    Life Insurance December 10, 2025By Roger Lawrence
    Share
    Twitter LinkedIn Email

    The 2025 edition of the Life Insurance Fact Book – the American Council of Life Insurers’ (ACLI) annual review into the inner workings of US-based life insurance company balance sheets – was published in early November. As with previous years, I will be highlighting some notable and interesting takeaways from the Fact Book for a series of articles for Longevity and Mortality Investor, starting with this one, a review of key statistics for the US life insurance industry in general and some that have relevance for the life settlement industry in particular. 

    General Industry Performance in 2024 

    The number of life insurers continued its decline from 719 in 2023 to 711 in 2024 as further consolidation to streamline costs and, for mutuals, demutualisation continues to be popular so that additional capital can be accessed. The rise in foreign ownership continued, as the number of entities with overseas ownership grew from 101 to 109, or 15.3% of the total. Within that, Bermuda contributed a further 8 compared to 2023 – up to 30 now – and Japan is up 5 to 20. The biggest reduction was from the UK, down from 7 insurers to just 2 in 2024. 

    Total assets of life insurers rose from $8.74trn to $9.26trn (+5.9%) in another strong year for the industry, and total liabilities rose from $8.23trn to $8.73trn (+6.1%), which was notably more than the expansion of assets. 

    This shortfall in growth between assets and liabilities unsurprisingly led to a drop in Capital Ratios (CR), which measure straight surplus. The CR – including the asset valuation reserve (AVR, a reserve to smooth changes in asset prices), changed from 10.7% to 10.5% and, excluding the AVR, from 9.0% to 8.7%. Whilst these are drops, they should not be regarded as worrisome as they are simply reversals of the improvements seen last year. 

    The AVR rose 4.8% in 2024 to an aggregate $104bn whilst its sibling, the IMR (Interest Maintenance Reserve, which covers fixed income investments) shrunk 36.2% to $10bn as bond yields normalised during the year.  

    Life Insurance Products 

    For life insurance products, the picture was a mixed bag, with further increasing average face values of new policies offsetting stagnant sales figures. In addition, we saw a return to growth in individual policy sales and a reduction in group sales, which is a reversal of the unusual spike in group sales seen in 2023 (that arose from changes in reinsurance cession). This may have been an indication that pressure on household finances eased as inflation abated, but there were still heightened levels of policy surrenders and lapses. 

    Individual policy in-force face amounts were $14.07trn at the year-end, marginally up from $13.98 trn (+0.7%) with the smaller amount of group policy face falling 3.1% from $8.10trn to $7.85trn. In total, all life policy in-force face changed from $22.15trn to $22.01trn (-0.7%). 

    Despite the fall in overall policy face amount, policy reserves all rose. For individual policies, reserves rose 4.0% from $1.656trn to $1.722trn, and group business reserves changed from $0.194trn to $0.203trn (+4.8%). 

    Premium income on life products was much stronger, increasing from $122bn to $173bn (+42.2%) but this was a reversal from 2023’s equivalent, likely as a result of a reversion to normal reinsurance patterns. 

    Claims paid in individual contracts rose over the year in aggregate. Contractual payments from death claims were slightly down from $66.3bn to $66.2bn (-0.2%) but surrender payments rose from $35.8bn to $44.2bn (+23.7%). Although a much smaller group by value, surrenders on group policies fell from $5.8bn to $2.7bn, a fall of 52.8%. As we have seen with new sales and premium payments, 2023 seems to have been an outlier; surrenders on group policies over both 2023 and 2024 rose from $1.1bn to $2.7bn, a significant rise, and for individual policies over the same period, the figures also show a large rise, from $28.8bn to $44.2bn. 

    It would appear that this increase in surrender values paid out mostly arises from holders of policies with higher encashment values choosing to surrender. Although lapse rates are still above 2022 values, over 2024 they have reduced compared to 2023. Individual policy lapse rates in 2023 fell from 7.3% to 6.6% whilst those for group contracts rose only marginally from 3.8% to 4.0%. The equivalent surrender rate for individual policies is 1.3%, up from 1.2%, whilst group surrenders are in rounding error territory, seemingly unchanged at 0.1%. 

    New business excluding a small amount of credit insurance was a much more mixed picture. New life products issued by face and number are shown in Figure 1 below. 

    Figure 1: US Life Insurance New Product Issuance, 2023-2024, $trns 

    Fig1

    Source: ACLI Life Insurers Fact Book, 2025 Edition. Totals include credit insurance 

    We will look at these various figures in more detail in further editions of Longevity and Mortality Investor. However, the immediate takeaway is that 2024 was a year of recovery after a difficult 2023 for households financially as inflation spiked before ebbing away. Looking at individual years can be misleading, and policyholder behaviour does not conveniently sit within calendar year conventions, so whilst new policy sales are not yet up to full strength and cancellation rates appear to have been above trend, the pattern within the year may have been more favourable towards the end. 

    Last year, we looked at the rise in death benefits paid out and also at how the “Covid curve” was developing. The ACLI’s published US mortality data is one additional year out of date than the life insurer data, so is not particularly meaningful to industry professionals who are much closer to current developments. All this data does is to confirm that their observations are as we know: 2020 and 2021 experienced the main heightening of mortality, and that subsequently, mortality rates were slow to return to 2019 levels and beyond (Figure 2). We don’t intend to look at this again in future. 

    Figure 2: US Crude Death Rate per 1,000 Americans 

    Fig2

    Source: ACLI Life Insurers Fact Book, 2025 Edition 

    Annuity Business 

    Finally, a shorter summary of the figures for annuities. Annuities represent approximately two thirds of life insurers’ reserves and so remain important. 

    Figure 3: US Life Insurance Company Net New Contributions, $bns: 

    Source: ACLI Life Insurers Fact Book, 2025 Edition 

    Figure 4: US Life Insurance Company Annuity Reserves, $trns: 

    Source: ACLI Life Insurers Fact Book, 2025 Edition 

    In 2023, we saw an unusual rise in individual annuities and a shrinkage in group, suggesting some transfers out to individual policies, but in the main it was due to variances in the amounts of reinsurance coverage being used by some insurers, something that has not been so pronounced in 2024.  

    However, taken as a whole we can see a significant continued growth with net new considerations equivalent to 10% of net reserves. The reserves themselves may have reduced to a small degree as a result of risk-free yields having risen during the year, but this still suggests activity remained robust in this business sector relative to historic levels. 

    Conclusion 

    As with previous years, the US life insurance industry had a solid 2024 from a balance sheet perspective and continues to be healthy from a risk perspective. Whilst liability growth outpaced asset growth last year, the difference was minimal, and the legacy of the Covid-19 pandemic still appears to be diminishing, to the point where, as I mentioned previously, unless something extraordinary happens, it will not be considered for this article next year.  

    Whilst capital ratios also retreated slightly, this appears to be more of a reversion to the norm as opposed to anything particularly concerning, so institutional investors with alternative investments that carry exposure to US life insurers – life settlements, life ILS, life-contingent structured settlements, for example – remain connected to an industry that was, as of the end of 2024, in good health. 

    Roger Lawrence is Managing Director at W L Consulting 

    Any views expressed in this article are those of the author(s) and may not necessarily represent those of Longevity & Mortality Investor or its publisher, the European Life Settlement Association

    2025 - December Analysis Commentary Volume 1 Issue 3 – December 2025
    Share. Twitter LinkedIn Email

    Related Posts

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026By Dr. Jyotsna Kamble

    Better Mortality Analytics Will Unlock the Next Phase of Life Settlement Growth

    April 9, 2026By Liam Bodemeaid

    US Life Insurers’ Ample Capital, Liquidity to Support Ratings in 2026

    February 25, 2026By Jamie Tucker and Jack Rosen

    Higher Sales and Lower Lapse Counts but Rising Exit Values for US Life Insurance Market

    February 11, 2026By Roger Lawrence
    Latest Issue

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.